



Cite this: *Chem. Commun.*, 2023,
59, 14745

Received 11th October 2023,
Accepted 10th November 2023

DOI: 10.1039/d3cc05006h

rsc.li/chemcomm

Biohybrid neural interfaces: improving the biological integration of neural implants

Marjolaine Boulingre,  Roberto Portillo-Lara  and Rylie A. Green *

Implantable neural interfaces (NIs) have emerged in the clinic as outstanding tools for the management of a variety of neurological conditions caused by trauma or disease. However, the foreign body reaction triggered upon implantation remains one of the major challenges hindering the safety and longevity of NIs. The integration of tools and principles from biomaterial design and tissue engineering has been investigated as a promising strategy to develop NIs with enhanced functionality and performance. In this Feature Article, we highlight the main bioengineering approaches for the development of biohybrid NIs with an emphasis on relevant device design criteria. Technical and scientific challenges associated with the fabrication and functional assessment of technologies composed of both artificial and biological components are discussed. Lastly, we provide future perspectives related to engineering, regulatory, and neuroethical challenges to be addressed towards the realisation of the promise of biohybrid neurotechnology.

Introduction

Neural interfaces (NIs) are devices that enable direct communication with the nervous system by leveraging the electrical excitability of nervous tissues to stimulate and/or record neural activity. NIs have been widely implemented in the management

of neurological disorders affecting either the central (CNS) or the peripheral nervous systems (PNS).^{1–6} They have also been extensively used to develop brain–machine interfaces (BMIs) to control neuroprostheses and other assistive devices.^{7,8} In general, NIs rely on the use of arrays of electrodes that can be implantable or non-implantable.⁹ Non-implantable electrodes can be used to monitor brain signals from the scalp *via* electroencephalography (EEG),¹⁰ which circumvents the need for surgical implantation but limits spatial and temporal

Department of Bioengineering, Imperial College London, South Kensington, London, SW7 2AZ, UK



Marjolaine Boulingre

Marjolaine Boulingre is a PhD student in the Department of Bioengineering at Imperial College London. She received her Master's degree in Life Sciences Engineering from Ecole Polytechnique Fédérale de Lausanne (EPFL) in 2022. Before joining the Green lab, she conducted her Master Thesis at Harvard School of Engineering and Applied Sciences (SEAS) within the Mooney lab, where she was involved in the development of soft conductive hydrogel scaffold for neural tissue engineering. Her current research interest focuses on developing next-generation bioelectronic devices that integrate cellular components to improve tissue integration.



Roberto Portillo Lara

Dr Roberto Portillo Lara is a biomedical scientist and bio-engineer whose research focuses on the development of tissue engineering and regenerative medicine technologies for theragnostic applications. Throughout his career, he has been involved in variety of projects with a strong translational component, ranging from engineering smart wound dressings, surgical bioadhesives and systems for controlled drug release, to cardiovascular, orthopaedic, and musculoskeletal tissue analogues. At Imperial College, he leads the "Living Electrode" project, a multi-disciplinary effort aimed at developing tissue-engineered neural interfaces that could be biologically integrated into the host in order to drive the next generation of implantable bioelectronics.



resolution.¹¹ In contrast, implantable devices such as the Utah electrode array (UEA) or electrode leads for deep brain stimulation (DBS) are implanted into the cortex or deep brain structures, providing higher resolution for electrical stimulation (ES) and recording due to the intimate contact with the host tissues.¹² Despite these advantages, conventional implantable NIs often undergo poor biological integration into the surrounding tissues, which in turn hinders long-term applications and clinical translation.

The implantation of an electrode array into the neural parenchyma triggers an inflammatory process mediated by the immune system, leading to a biological response known as the foreign body reaction (FBR) (Fig. 1). The initial trauma and the disruption of the blood brain barrier (BBB) result in the release of circulating blood cells and proteins that trigger an acute inflammatory response at the implant site^{13,14} (Fig. 1A). Early after implantation (0–24 h), migratory neutrophils increase vascular permeability and mediate monocyte recruitment and differentiation into macrophages *via* soluble pro-inflammatory cytokines. Activated macrophages attempt to phagocytose and degrade the implant, which results in electrode damage,¹⁵ increased impedance,¹⁶ and overall reduced device performance (Fig. 1C). Resident cells in the CNS such as microglia and astrocytes also become activated and contribute to this acute immune response.^{17–20} For chronically implanted devices (> 4 weeks), the sustained inflammation gives way to a fibrotic process that ultimately leads to the formation of a fibrous scar that encapsulates and isolates the implant^{21–23} (Fig. 1B). In the context of ES, this physical barrier increases the level of charge injection required to elicit tissue activation, which induces further tissue damage and electrode degradation.²⁴ Local tissue trauma may also be exacerbated due to mechanical mismatches and implant micromotion caused by normal respiratory and cardiovascular

functions.^{25,26} This is mainly because conventional NIs rely on electrode arrays made from stiff and inert materials such as platinum (Pt), platinum–iridium (Pt–Ir) or stainless steel,^{27,28} which are mechanically distinct from the soft and viscoelastic neural tissues. The perpetuation of local tissue damage further aggravates neuronal depletion leading to a reduction of approximately 40% in the number of viable neurons at the device–tissue interface.²⁹

Chronic inflammatory responses have been shown to hinder implant biointegration, longevity, and performance, and constitute one of the main limitations precluding the long-term applications of implantable NIs. The large majority of studies describing the negative effects of the FBR on implant performance have relied on research performed on animal models. However, clinical evidence has shown that the long-term implantation of NIs is also associated with the onset of inflammatory and fibrotic responses in human patients. For instance, post-mortem analysis has revealed that a UEA retrieved 7 months after implantation exhibited signs of fibrotic encapsulation and peri-implant tissue damage.³⁰ Electrode tip degradation has also been observed following post-mortem explantation of UEAs after 987 and 182 days, with higher degrees of electrode damage corresponding to longer implantation timelines.¹⁵ Therefore, strategies aimed at mitigating the negative effects of the FBR and improving the long-term safety and performance of NIs have gathered significant research interest.

The biomechanical mismatch between soft living tissues and stiff implants is a major factor influencing the degree of the FBR. Therefore, implant design strategies are moving away from conventional stiff materials towards flexible and conformable alternatives based on biomimetic design.^{31–39} A variety of novel electrode substrates made from elastomers or organic materials combined with conductive polymers (CPs),⁴⁰ carbon nanotubes (CNTs), or graphene (GF) have been developed for this application.⁴¹ Bio-integrative strategies based on surface modification or the incorporation of biomaterial coatings that provide a more biomimetic interface have also been widely explored.^{37,42,43} Lastly, as the field of NIs continues to evolve, there has been a shift towards alternate modalities for neural interfacing. For instance, neural recording through intracranial blood vessels *via* endovascular stent electrode arrays has emerged as a promising alternative to conventional implantation techniques.^{44,45}

Strategies that improve implant resolution and selectivity are also needed to enhance the discrimination of neuronal activity and to enable the stimulation of specific cells or cell populations. To this end, it has been hypothesised that biohybrid design approaches may be used to engineer high-resolution and chronically-stable bioelectronic interfaces by promoting the integration of implantable devices into the host tissues at the cellular level.⁴⁶ This feature article will focus on the main experimental strategies in bioelectronics research aimed at engineering the device–tissue interface through the integration of biomaterial- and cell-based strategies. First, the use of biochemical and biophysical cues to guide the fate of



Rylie A Green

Prof Rylie Green, FIET, is the Head of Bioengineering at Imperial College London. Prof. Green has developed a range of innovative materials to address the limitations that hinder the development of next-generation bioelectronic devices. Her focus has been in developing electrode technologies that are stretchable and mediate improved electrical charge transfer with the body, including pioneering living bioelectronics. She has also

developed wearable diagnostic devices and drug delivery systems for localised chemotherapy. This research has initiated collaborations with Galvani Bioelectronics, Cochlear Ltd and the US Department of Defense. She is an Associate Editor for APL Bioengineering, Advanced Bionanomedicine and Biomaterials.






Fig. 1 Tissue responses to neural implants and their impact on device performance. (A) The acute immune response. Upon implantation, plasma proteins adhere to the electrode surface triggering PRR-mediated signalling pathways in microglial cells, astrocytes, and infiltrating neutrophils. Activated cells secrete pro-inflammatory cytokines (TNF, IL1 β , IL2) and chemokines (CCL2) increasing BBB permeability, as well as macrophage infiltration, activation, and polarization into an M1 pro-inflammatory phenotype. ROS and the activation of the complement cascade further contribute to neurotoxicity. (B) The chronic immune response. Macrophages polarize into an M2 phenotype and release anti-inflammatory cytokines (TGF β , IL4, IL10). Astrocytes, microglia, and macrophages fused into multi-nucleated giant cells form a scar that encapsulates the implant. Pro-angiogenic factors such as VEGF and PDGF are involved in the vascularisation of the capsule surrounding the electrode. (C) Electrical model of the electrode-tissue interface. The FBR increases electrode impedance and decreases CSC over time, resulting in reduced SNR and increased risk of overpotential. BBB (blood brain barrier), CCL (chemokine ligand), CCR (chemokine receptor), CSC (charge storage capacity), IL (interleukin), ILR (interleukin receptor), PDGF (platelet-derived growth factor), PRR (pattern recognition receptor), ROS (reactive oxygen species), SNR (signal-to-noise ratio), TGF β (tumour-growth factor β), TGF β R (tumour-growth factor β receptor), TNF α (tumour necrosis factor α), TNFR (tumour necrosis factor receptor), VEGF (vascular endothelial growth factor).

endogenous cells at the implant site is discussed. Second, strategies based on biomaterial carriers for the delivery of exogenous cells to mediate implant biointegration are reviewed. Overall, biohybrid approaches may provide safer, longer-lasting, and more efficacious alternatives to conventional NIs by incorporating tools and principles from regenerative medicine and tissue engineering into bioelectronic development.

Modulation of endogenous host cells

Implant surface modification strategies have been explored to instruct the growth and development of endogenous cells that could in turn mediate device biointegration. Moreover, the controlled release of biochemical cues and the delivery of biophysical stimuli has also been explored to elicit specific biological responses towards



ameliorating the FBR and enhancing implant longevity and performance.

Biochemical cues: surface functionalisation, bioactive coatings, and controlled release

Inert materials such as Pt or graphite remain the most commonly used electrode substrates for NIs, while polymers such as polyimide (PI) or poly(dimethylsiloxane) (PDMS) are often used for insulation and encapsulation.²⁷ Due to the lack of biological cues, these devices are intrinsically unable to support cell development to establish intimate contact with the host tissues. Because of this, the incorporation of biological cues to guide the fate of endogenous cells upon implantation has been widely investigated in the literature. One approach to present biological cues to endogenous cells relies on the functionalisation of the implant surface with bioactive molecules. For instance, the immobilization of cell adhesion proteins such as laminin⁴⁷ or neural adhesion protein L1⁴⁸ on the electrode surface has been shown to promote the growth and development of endogenous cells at the interface (Fig. 2A). Neuronal survival and neurogenesis can be promoted *via* specific growth factors involved in neuroplasticity, such as brain-derived neurotrophic factor (BDNF).^{49,50} Molecules aimed at reducing microglial activation and gliosis can also be integrated at the interface to ameliorate neurotoxic responses.^{51,52} Moreover, bioactive patterns can be formed on the electrode surface by alternating cell adhesion inhibitors and cell-adhesive motifs⁵³

to mimic tissue architectures found *in vivo*. Different strategies to functionalise the electrode surface with bioactive molecules have been reported in the literature. Although physical absorption is a versatile and facile approach, this often results in the formation of weak, non-specific, and reversible non-covalent bonds.⁵⁴ In contrast, techniques based on chemical absorption such as silane chemistry produce covalent bonds that are comparatively stronger and can be used to graft proteins to different substrates.⁵⁵ Surface pre-treatment with oxygen plasma has been explored to enhance biomolecule functionalisation by modifying implant hydrophilicity. However, this type of approach could result in unwanted effects such as etching of the underlying materials.⁵³ Alternatively, surface hydrophilicity can be modulated to augment the adhesion of bioactive molecules without compromising implant integrity.⁵⁶ Surface functionalisation *via* grafting of bioactive molecules directly to the implant surface enables the preservation of device footprint. However, this strategy is limited by the concentration of molecules that can be grafted, as well as the type of chemistry needed and the surface area available for functionalisation.

Another approach to deliver bioactive stimuli to the implant site relies on the encapsulation of soluble cues into biodegradable material-based coatings (Fig. 2B). In this context, hydrogels provide several advantages owing to their high-water uptake capacity and their similarity to the native extracellular matrix (ECM). Hydrogels have been widely employed as




Fig. 2 Biochemical cues to modulate endogenous cell fate. (A) Biomolecule surface functionalisation strategies. Schematic depicting the functionalisation of silicone electrode arrays with neural adhesion molecule L1 (middle) and fluorescence micrograph showing neuronal attachment on L1-coated probes (β -tubulin III is shown in green and cell nuclei in blue) (right) (reproduced with permission from ref. 48). (B) Biomaterial coating strategies for controlled release. Schematic showing PVA-PEDOT CHs biofunctionalized with NGF (middle) and fluorescence micrographs showing neurite outgrowth on CHs with soluble NGF (top) NGF-functionalised CHs (bottom) (reproduced with permission from ref. 57). (C) Microfluidic delivery. Schematic of a flexible penetrating microelectrode arrays with integrated microfluidic structures (middle) and fluorescence micrograph showing local delivery of Dextran Texas Red (red) at the interface (cell nuclei shown in blue) (right) (reproduced with permission from ref. 68). (D) Biomaterial-based electrode constructs. Schematic of ECM-based microelectrodes composed of collagen I and fibronectin (middle) and fluorescence micrograph showing cortical neurons growing on ECM-based electrodes (top), compared to parylene controls (bottom) (β -tubulin III is shown in green and cell nuclei in blue) (reproduced with permission from ref. 69).



reservoirs for the controlled release of neurogenesis-promoting drugs and growth factors, such as BDNF or nerve growth factor (NGF),⁵⁷ as well as anti-inflammatory drugs such as dexamethasone.^{58,59} Moreover, biological cues could also be integrated into coatings that enhance the electrochemical performance of electrodes. CPs such as polypyrrole (Ppy) or poly(3,4-ethylenedioxythiophene) (PEDOT) have been functionalised with biological cues such as laminin-derived peptides⁶⁰ or RGD motifs⁶¹ to produce coatings that could tune both charge transduction and cell development at the interface. For instance, Ppy films doped with hyaluronic acid (HA) with high molecular weight were used as electrode coating and exhibited reduced cell attachment.⁶² Such coating could be used to diminish scar tissue formation. Ppy has also been used in conjunction of polydopamine (PDA) to form conductive biomaterial coating supporting cell adhesion.⁶³ Furthermore, research from our group has shown that the co-incorporation of laminin peptide dopants and neurotrophic growth factor (NGF) into PEDOT-based coatings could effectively promote neurite outgrowth *in vitro*.^{64,65} However, this biofunctionalization strategy was also shown to disrupt the PEDOT matrix, rendering it more brittle and subject to delamination.⁶⁴ To overcome this, our group and others have reported the engineering of interpenetrating conductive hydrogels (CHs) *via* electrochemical polymerisation of the CP chains using an immobilized dopant.⁶⁶ CHs hold great potential to develop controlled release systems for the delivery of drugs and other charged molecules *via* electroactive release.^{57,58,67} However, non-electroactive hydrogels could also be implemented for this application by fine-tuning the polymer composition, the degree of crosslinking, or the degradation rate of the scaffold. Despite these advantages, hydrogel coatings are susceptible to delamination during implantation, and they can only be loaded with a finite concentration of molecules. Furthermore, hydrogel swelling could significantly increase device footprint, resulting in greater tissue displacement upon implantation.

Despite the advantages of ECM-based coatings, these nano-scale structures are often rapidly biodegraded *in vivo*, which largely precludes their ability to modulate tissue responses across chronic timeframes. One approach to address this limitation is the integration of microfluidic structures within NIs to enable sustained and prolonged delivery of neurogenic factors or anti-inflammatory drugs⁶⁸ (Fig. 2C). However, the integration of a microfluidic component could greatly increase the footprint of the device, which increases tissue displacement and compression during implantation. To address this limitation, previous groups have explored the engineering of electrode constructs that are predominantly composed of native ECM components. For instance, a study by Shen *et al.* reported the fabrication of ECM-encapsulated microelectrodes, which possessed similar dimensions and exhibited comparable performance to conventional silicon-based arrays *in vivo*. These ECM-based microelectrodes were shown to support the formation of a dense layer of viable neurons on the implant surface, while also undergoing reduced neuroinflammation and glial scarring following chronic implantation in rats⁶⁹

(Fig. 2D). Furthermore, the ability of biological materials to be effectively biodegraded *in vivo* could be leveraged to engineer transient bioelectronics that could be cleared from the body after the therapeutic effect has been achieved. This approach could address issues related to chronic tissue damage associated with persistent NIs, while also circumventing the need for surgical retrieval.^{70,71}

Physical cues: implant architecture, surface topography, and device form factor

The physical structure of the ECM provides specific architectures that influence cell migration and differentiation *in vivo*. Therefore, the recapitulation of biophysical cues found in the native ECM has been explored to influence the fate of endogenous cells at the interface^{56,72} (Fig. 3A). Based on this biomimetic approach, the modulation of implant surface nano-roughness has been shown to increase neural cell attachment *in vitro*.^{73,74} As neurons and glial cells exhibit unique responses to different surface topographies, this strategy has been employed to modulate the neuron-to-glia coverage along the implant surface.^{75,76} Surface topography could be used to modulate the fate of immune cells such as macrophages by promoting their polarization towards pro- or anti-inflammatory phenotypes.^{77,78} Furthermore, increasing the electrode surface roughness also increases the active surface area, thus reducing impedance and enhancing the charge storage capacity (CSC).⁷⁹

NIs with novel form factors have been designed to promote tissue integration by incorporating open or perforated device architectures⁸⁰ (Fig. 3B). For instance, a pioneering study by Kennedy *et al.* reported the engineering of cone electrodes comprised of an insulated gold wire fixed inside a hollow glass cone.⁸¹ These glass structures were loaded with sciatic nerve segments, which promoted tissue ingrowth into the electrodes following intracortical implantation in rats and monkeys.^{81,82} Although long-term electrophysiological recordings could be obtained for up to 15 months after the implantation of single- and multi-electrode units, the low scalability of this approach greatly limits clinical implementation. More recently, polymeric materials such as parylene C (PaC) have been explored to fabricate electrode arrays using manufacturing techniques such as surface micromachining. For instance, PaC arrays with perforated sheath structures have been shown to improve tissue integration and the exchange of oxygen and nutrients upon implantation.⁸³ These arrays were also shown to produce stable neural recordings for up to 12 months following implantation into the rat motor cortex, while also enabling tissue ingrowth within the perforated structures.⁸⁴ Open architectures and compliant polymeric materials thus offer the possibility to establish more intimate contact with target cells by guiding tissue ingrowth within the device or reducing tissue damage at the interface. Despite these advantages, the preservation of structural integrity during and after implantation is critical to ensure optimal device performance. In addition, bespoke insertion methods such as shuttle devices³⁵ or transient coatings for probe stiffening are often required to aid the implantation of these types of NIs.^{85,86}






Fig. 3 Biophysical cues to modulate endogenous cell fate. (A) Topographical cues to direct cell adhesion and differentiation (reproduced with permission from ref. 56) (right). Fluorescence micrographs of β -tubulin positive (red) and GFAP positive cells (green) on nanoporous-Au surfaces (left) (adapted with permission from ref. 75 Copyright 2023 American Chemical Society). (B) Open and perforated electrode arrays and immunohistochemical staining showing tissue ingrowth into perforated parylene sheath electrodes (NeuN is shown in brown and GFAP in blue) (reproduced with permission from ref. 84). (C) Schematic of NeuE arrays mimicking subcellular neuronal structures and fluorescence micrograph showing the interaction between NeuE electrodes (red) and neurons (green) (reproduced with permission from ref. 90). (D) Schematic showing the delivery of injectable mesh electronics and fluorescence micrograph of cortical brain slices at 12 weeks post-injection (neurofilaments shown in red and NeuN in yellow, mesh electronics are shown in blue) (reproduced with permission from ref. 98).

A variety of biomorphic designs that recapitulate tissue architecture and mechanics have been explored to improve the long-term stability of NIs. For instance, the reduction of implant footprint has been shown to diminish macrophage activation and the FBR by minimising tissue damage upon implantation⁸⁷ (Fig. 3C). Millimetre-sized wireless NIs termed neural dust have been explored for the recording of electrical signals from nerves and muscles.^{88,89} In another study by Yang *et al.*, nano-scaled bioinspired electrodes were fabricated with recording sites that matched the size of the soma of pyramidal neurons.⁹⁰ These neuron-like electronics (NeuE) were implanted into mouse brains and produced stable recordings for up to 90 days post-implantation. However, one challenge associated with device miniaturization is the preservation of electrode properties, as reducing the surface area also increases electrode impedance. To overcome this limitation, surface roughening^{91,92} and electrode coatings^{93,94} could be employed to increase the surface area and reduce impedance, while also enhancing electrode performance and recording selectivity.

Another strategy to enhance electrode–tissue interaction is the design of mesh or cloud electronics that can spread within and establish intimate contacts with nervous tissues.⁹⁵ For instance, Liu *et al.* developed syringe-injectable mesh electronics, which were shown to support cell migration along the mesh when injected into rodent brains^{96,97} (Fig. 3D). These mesh electrodes were shown to enable long-term stimulation and recording,⁹⁸ while also resulting in reduced FBR when compared to flexible thin-film probes.⁹⁹ Another iteration of cloud electrodes was developed based on *in situ* electropolymerisation of PEDOT.^{100,101} PEDOT monomers could be

polymerized upon injection to form a polymer cloud that could spread beyond areas affected by neuronal depletion and interact with healthy neurons distal to the implant site.¹⁰² The long-term effects of *in situ* PEDOT deposition were investigated following injection into the hippocampus of rodents,¹⁰³ which showed no impairment in neural function. Similarly, deployable intracortical electrode arrays have been developed based on liquid crystal elastomers (LCEs), which also enabled recording from viable neurons away from the insertion site and the FBR-induced glial sheath.¹⁰⁴

Delivery of exogenous cell effectors

The functionalisation of NIs with live cells has emerged as a promising strategy to engineer biohybrid technologies that better approximate the properties and functionality of biological tissues.¹⁰⁵ It has been hypothesised that transplanted cells could establish physiological connections with the host nervous system and mediate implant biointegration at the device–tissue interface. Physiological communication between neurons mainly relies on chemical and electrical synapses.¹⁰⁶ While chemical communication is mediated by neurotransmitter release at the synaptic cleft, electrical communication is transmitted by cytoplasmic connections such as gap junctions. It can be hypothesised that mature endogenous cells would secrete factors guiding and directing the neurite extension of transplanted cells. This would mediate the establishment of chemical synapses between endogenous neurons and exogenous neurons.¹⁰⁷ Furthermore, because of physical vicinity,






Fig. 4 Delivery of exogenous cells to engineer the device–tissue interface. (A) Schematic showing direct cell engraftment *via* ECM adhesion proteins. Fluorescence micrographs of GFP-positive NPCs (green) cultured for 14 days on laminin-functionalised probes (autofluorescence in red) (middle) and 1 day after implant retrieval (right) (reproduced with permission from ref. 55). (B) Cell-laden biomaterial-based coatings. Schematic of layered living electrodes developed by Green *et al.* (reproduced with permission from ref. 116) (right). (C) Cellularised polymeric electrode constructs. SEM micrograph of a porous alginate scaffold embedded with carbon nanomaterials (middle) and fluorescence micrographs of encapsulated NPCs after 6 weeks in culture (Tuj1 shown in green, MBP in white, NPCs in red, and cell nuclei in blue) (right) (reproduced with permission from ref. 185). (D) Schematic of micro tissue-engineered neural networks (μ TENN). Fluorescence micrograph of μ TENN retrieved 1 month after implantation (GFP shown in green, NF200 in red, synapsin in purple, and cell nuclei in blue) (right) (adapted with permission from ref. 186).

cell-to-cell connections could be initiated between the two cell populations, thus mediating electrical communication and promoting neuronal integration.¹⁰⁸ This approach may enable more natural mechanisms of neuromodulation,¹⁰⁹ which in turn could reduce the risk of faradaic charge injection and the associated tissue damage.¹¹⁰ Different approaches to engineer biohybrid NIs have been reported in the literature,¹¹¹ including grafting cells directly to the implant surface *via* immobilised ECM adhesion proteins (Fig. 4A). For instance, Azemi *et al.*, investigated the functionalisation of silicon probes with laminin and murine neural progenitor cells (NPCs) to improve the biointegration of neural implants.⁵⁵ Their results showed that NPCs on the probes remained viable after implantation into the murine cortex, and that the implants underwent reduced fibrotic encapsulation compared to the controls. A different strategy currently under development by our group relies on the selective engraftment of biotinylated cells to streptavidin-functionalised implant surfaces. This molecular anchoring approach has already been used in the clinic to enhance the endothelialisation of arterial stents following angioplasty¹¹² and to increase neural cell attachment to biomaterial scaffolds.¹¹³ Although directly attaching cells to the electrode surface does not increase the footprint of the device, cell viability could be compromised due to shear stress experienced upon implantation.²⁵

Implant micro-displacement due to cardiorespiratory function induces constant mechanical stress and increases the

severity of scarring around the implant.^{25,38} Owing to their tuneable mechanical properties, hydrogel scaffolds can be used to attenuate noxious responses induced by tissue micromotion and mechanical mismatches. Furthermore, hydrogels constitute ideal carriers to enhance the viability of exogenous cells delivered to the device–tissue interface due to their biomimetic properties¹¹⁴ (Fig. 4B). For instance, Faveri *et al.*, reported the development of wire microelectrodes coated with a fibrin hydrogel containing encapsulated neurons or glial cells.¹¹⁵ Their results showed that both cell types were able to develop within the hydrogel, and that the biohybrid coating did not negatively impact the electrochemical performance of the electrodes. Another iteration of biohybrid NIs developed by our group consists of a tissue-engineered layered electrode coating. These living electrodes (LEs) are composed of a CH layer and a cell-laden biosynthetic hydrogel layer formed on top of a Pt electrode substrate.¹⁰⁹ The CH enhances the electrochemical properties of the underlying electrode, while the biosynthetic hydrogel enables the combined delivery of relevant bioactive cues to control the fate of the encapsulated cells.¹¹⁶ This approach highlights the versatility and modularity of biomaterial systems for the development of tissue-engineered components that could be incorporated into biohybrid NIs.

Tissue-engineering design criteria for biohybrid NIs

Although neurons constitute the main functional cell type in the nervous system, glial cells such as astrocytes and



oligodendrocytes are key modulators of neural function.^{117–119} Because of this, the engineering of functional neural constructs *in vitro* has been shown to rely heavily on the contribution of a functional glial component.^{120,121} For instance, work from our group showed that hydrogel carriers composed of poly(vinyl alcohol) (PVA) co-polymerised with sericin and gelatin (PVA-SG) could effectively support the differentiation of PC-12 cells.^{122,123} However, the restrictive polymer network failed to support the development of primary astrocytes, which in turn compromised the survival of co-encapsulated murine NPCs.¹²⁴ These observations highlight the relevance of the cell phenotypes employed and the conditions in which they are maintained *in vitro* to fabricate complex heterocellular neural constructs. In recent years, patient-derived induced pluripotent stem cells (iPSCs)¹²⁵ have emerged as a promising resource for personalized tissue-engineered technologies.^{126–129} As iPSC-derived NPCs have been shown to differentiate into various neural phenotypes,¹³⁰ they represent an ideal platform to engineer immunocompatible biohybrid NIs. Issues related to the sourcing of cells with limited or aberrant functionality may hinder this strategy in patients affected by trauma or disease.^{131,132} However, genome editing and cell reprogramming technologies may be employed to engineer designer cell phenotypes tailored to specific applications.^{133,134} Furthermore, bio-instructive materials could be rationally designed to deliver synergistic combinations of physicochemical cues for biofabrication. In this regard, four main design aspects may be considered for the development of tissue-engineered constructs for biohybrid NIs.¹³⁵

Biological stimuli. The recapitulation of native cues found in biological tissues through the use of material-based scaffolds is fundamental for neural tissue engineering.¹³⁶ Although synthetic materials such as PVA or poly(ethylene glycol) (PEG)¹³⁷ enable precise control over the physical properties of scaffolds, the lack of physiological cues often hinders cell development. To address this, synthetic polymers could be functionalised with ECM adhesion cues, such as the widely used arginine-glycine-aspartic (RGD) motif.^{138–141} They could also be used in combination with natural polymers such as gelatin and collagen to produce biosynthetic composites with enhanced bioactivity.^{142,143} The use of biosynthetic materials also enables scaffold remodelling and biodegradation *via* cell-secreted proteases such as matrix metalloproteinases (MMPs).¹⁴⁴ In the context of biohybrid NIs, the precise modulation of scaffold biodegradability is fundamental to support the maturation of tissue-engineered constructs *in vitro*. This property is also critical to allow endogenous tissue ingrowth to form a chronically-stable interface upon implantation. For instance, a biosynthetic hydrogel system developed by our group has been shown to support the development of primary NPCs into synaptically active neural constructs.¹⁴⁵ Moreover, these scaffolds could also support neural tissue ingrowth *ex vivo*, which highlights the potential of this biomaterial system as a platform to engineer bio-integrative NIs.

Biophysical features. Scaffold micro-architecture greatly influences the determination of cell fate through the

modulation of cell morphology and the promotion of specific gene expression pathways.¹⁴⁶ The porosity of the polymer network also determines the movement of nutrients, bioactive factors, and metabolic by-products, as well as the ability of cells to migrate and spread across the scaffold.¹⁴⁷ Biomaterial scaffolds with specific fibre alignments and diameters have been shown to guide neurite extension and the differentiation of neural stem cells (NSCs) into neurons.¹⁴⁸ In turn, this property may be leveraged to engineer biohybrid NIs with bio-instructive architectures. For instance, Tang-Shomer *et al.*, reported the engineering of a biohybrid NI based on thin and micro-patterned silk films.¹⁴⁹ Their results showed that micro-grooves on the films could promote the alignment of astrocytes and nascent neuronal processes, but had no effect on the alignment of mature axons. Therefore, scaffolds with defined biophysical features hold great potential to elicit cell-specific responses without the need for soluble factors. This approach could also reduce manufacturing costs and complexity and overall help facilitate clinical translation.

Mechanical properties. As multiple cellular pathways are influenced by mechanoresponsive mechanisms, the modulation of scaffold stiffness and viscoelasticity has been explored to guide neural proliferation and differentiation.^{150,151} Previous studies have shown that soft biomaterial substrates could enhance neuronal maturation and branching.^{152–156} They have also been shown to support optimal morphological development of encapsulated brain organoids.¹⁵⁷ Soft and viscoelastic biomaterials have thus been widely explored to mimic the properties of nervous tissues and enable targeted cell mechanoregulation.¹⁵⁸ Hydrogels are remarkably advantageous in this regard, as their mechanical properties can be readily modified by varying the polymer type and concentration, as well as the crosslinking strategy.¹³⁷ Although soft hydrogels (0.1–10 kPa) have been shown to be more permissive for neuronal culture, glial cells generally require stiffer substrates (0.5–10 kPa) for adequate development *in vitro*.¹⁵⁹ Furthermore, NSCs have been shown to preferentially differentiate into neuronal lineages when cultured on softer substrates (0.1–0.5 kPa), whereas stiffer scaffolds (1–10 kPa) are often conducive to glial differentiation.¹⁶⁰ The mechanical properties of biomaterials are also of particular importance when designing biohybrid NIs in order to prevent noxious tissue responses.¹⁶¹ Therefore, there is a need to develop tailorable and multi-functional biomaterials to meet the mechanical requirements associated with different aspects of biohybrid design.

Electrical cues. Neural cell populations, including neurons, glia, and NSCs have been shown to respond to a wide range of electroconductive substrates and stimulation regimes *in vitro*.¹⁶² Similarly, the intrinsic electrical activity of neurons has been shown to play a role in the maturation of cortical networks *in vivo*.^{163–166} Because of this, there has been a growing interest in the development of electroconductive materials for a variety of applications in neural engineering.^{167,168} Conductive scaffolds could be used to enhance intrinsic neuronal activity and strengthen newly formed synapses without the need for exogenous electrical stimuli.¹⁶⁹ Different



conductive materials have been explored for this application, including gold nanostructures^{170,171} and carbon allotropes such as GF and CNTs.^{167,172} For instance, CNT grids for neuronal culture have been shown to promote the formation of neural networks with enhanced neurite outgrowth and synaptic activity *in vitro*.^{173,174} Conductive scaffolds are also ideal substrates to study the effect of exogenous ES on neural growth and differentiation. A study by Koppes *et al.* demonstrated that ES resulted in enhanced neurite outgrowth in scaffolds loaded with single-walled CNTs, compared to controls without ES.¹⁷⁵ Similarly, ES of human NSCs cultured on graphene oxide foams has been shown to promote cell proliferation and neuronal differentiation.¹⁷⁶ CPs have also been used to engineer composite scaffolds for neuronal culture¹⁷⁷ and have been widely used as coatings to improve electrode performance in biomedical implants.¹⁷⁸ Although this approach has been widely explored for the fabrication of CHs, the incorporation of nanomaterials could significantly alter the mechanical properties of hydrogels. Moreover, concerns related to nanotoxicity and the fate of nanomaterials upon scaffold biodegradation remain. Therefore, there is a need to increase our understanding on the pharmacokinetics of nanomaterials and their interactions with proteins and cells *in vivo* in order to prevent potential neurotoxic effects.

Considerations for biohybrid NI fabrication

The integration of cellular components into the design of implantable NIs could enable the possibility of directly interfacing devices with the nervous system by harnessing intrinsic physiological mechanisms. However, the technological and biological complexity of biohybrid implants raises multiple challenges related to their fabrication, functional characterisation, and clinical translation. One challenging aspect of biohybrid fabrication are the potential compromises between device functionality and the viability of the tissue-engineered components. For instance, while soft biomaterial coatings may promote neuronal survival at the interface and help alleviate the FBR, they are susceptible to swelling and delamination and may be lost upon tissue insertion.^{14,179} Several studies reported swelling-induced delamination of hydrogels bound to rigid substrates.^{180,181} CH coating loss was also observed following implantation of CH-coated cochlear implants¹⁸² and DBS electrode arrays.¹⁸³ As the use of stiffer materials that could better withstand implantation could compromise cell development at the interface, alternative strategies may be explored. Multiple techniques are available to enhance the adhesion of biohybrid coatings to electrode substrates, which include surface roughening to increase hydrogel grip¹¹⁵ or chemical pre-treatment to form functional handles.¹⁸⁴ For instance, biohybrid LEs developed by our group rely on an electrochemically deposited pre-layer of PEDOT/*p*-toluenesulfonate (pTS) to enhance the mechanical grip of the CH to the underlying electrode substrate.⁶⁶

Biohybrid NI design should aim to maximise the synergy between different experimental approaches according to the intended application in order to streamline technology development. For instance, the use of growth factors or cytokines to instruct cell fate for biofabrication may be circumvented by tailoring scaffold mechanics and architecture, or *via* targeted ES. The neurotrophic support provided by accessory feeder cells could be leveraged to avoid the need for growth factor or cytokine supplementation. Moreover, the delivery of exogenous cell effectors may be bypassed all together in some cases by exploiting instead the capabilities of resident host cells or migratory cells recruited to the implant site. Therefore, biohybrid NIs could be designed to leverage the complexity of the *in vivo* environment in order to simplify technology development and streamline clinical translation.

As the field of bioelectronics continues to shift towards the use of flexible organic materials for device fabrication, the direct integration of cellular components into the NI structure has been explored (Fig. 4C). For instance, neuron-electrode interfaces composed of silk films co-patterned with cells and electrodes have been used for neural recording and ES *in vivo*.¹⁴⁹ Viscoelastic CHs composed of alginate and carbon allotropes have been shown to support the growth and differentiation of NPCs into both neurons and glia.¹⁸⁵ As these CHs exhibited conductivities ranging between 4–10 S m⁻¹, they hold great promise to fabricate implantable NIs for targeted ES. Micro-tissue engineered neural networks (μ TENNS) have been engineered based on agarose hydrogel microcolumns filled with collagen and laminin to guide the ingrowth of neural 3D aggregates across the lumen^{105,186} (Fig. 4D). These tubular constructs may be used to modulate target tissues *via* synaptic connections established *de novo* between NIs and the host nervous system.^{187,188}

Pre-clinical evaluation

Technical challenges may be encountered when evaluating the performance of active devices composed of both artificial and biological components. Although *in vitro* models have been developed to mimic some aspects of chronic implantation,¹⁸⁹ *in vivo* models remain the gold standard as they provide the highest physiological relevance. Multiple transgenic models of neurological disorders have also been established,¹⁹⁰ which provide more accurate platforms for the assessment of therapeutic NIs. Although post-mortem analysis of explants has been traditionally used for functional evaluation, this usually requires extensive tissue processing and is only representative of discrete endpoints. Non-invasive imaging techniques are therefore required for real-time evaluation of device performance and to monitor tissue responses *in vivo*. Intravital imaging techniques such as two-photon microscopy^{191,192} and clinical imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) may be used for this application. These techniques could not only be used to monitor the development of biohybrid implants *in situ*, but also to assess the degree of biointegration and FBR without the need for implant retrieval.^{193,194} To achieve this, our group and



others have focused on the development of advanced biomaterials for soft bioelectronics that are compatible with clinical imaging techniques such as MRI. Alternatively, emerging neuroimaging techniques based on functional ultrasound have been shown to enable large-scale and high-resolution neural imaging in human patients.^{195,196} In addition, near-infrared fluorescent (NIR) imaging¹⁹⁷ or MRI¹⁹⁸ may be used in combination with labelling techniques to monitor the fate of exogenous cells across chronic timeframes.

Electrochemical characterisation *via* electrochemical impedance spectroscopy (EIS) or cyclic voltammetry (CV) may be carried out to assess electrode performance and the degree of fibrotic encapsulation.^{199,200} When performed *in vivo*, faster CV scan rates may be used in order to reduce anaesthesia time, as well as the risk of charge build-up and faradaic damage. It is also important to consider the impact of the stimulation delivered for electrochemical characterisation on the biology of the tissue-engineered components and the host tissues. Moreover, as cellularised constructs are closely integrated with active electrode systems for biohybrid fabrication, it is crucial to better understand the influence of electrical stimuli on the fate of complex neural constructs. To this end, multi-electrode array (MEA) systems have been developed to enable real-time, label-free and high-throughput electrophysiological monitoring *in vitro*.²⁰¹ In addition, custom-built devices could be developed to better approximate specific physiological scenarios or to accommodate the requirements of NIs with bespoke formats.²⁰² However, experimental findings from *in vitro* ES studies remain poorly translatable, which is due in part to the lack of standardised set-ups and protocols. To address this limitation, computational *in silico* models have been explored to enhance the reproducibility of ES protocols and streamline clinical translation.²⁰³

Future perspectives

The realisation of biohybrid NIs that could one day be delivered to human subjects presents multiple engineering hurdles that need to be addressed to ensure implant and patient safety. For instance, the integration of wireless and battery-free capabilities for transcutaneous operation could help ameliorate surgical risks, while also extending device longevity and improving user experience.^{204,205} Wireless brain-computer interface (BCI) systems such as the one developed by the BrainGate research consortium are already being implemented in the clinic to allow tetraplegic patients to control point-and-select interfaces.²⁰⁶ However, despite the advantages of wireless interfacing, this approach may hinder information transfer rates and raise concerns related to data safety and protection.²⁰⁷ In addition, several neuroscientific questions remain unanswered, such as the long-term effects of neuromodulatory devices on brain function. Adverse effects such as depression, cognitive decline, and personality changes have been reported in Parkinson's Disease patients undergoing DBS.²⁰⁸ Although these effects could be partly attributed to medication or disease

progression, the impact of chronic implantation and ES regimes remains to be elucidated. Moreover, if transplanted cells are able to establish synaptic connections with the host, they could potentially disturb endogenous neural activity due to ectopic activation or inhibition. Exogenous stem or progenitor phenotypes could also migrate out of the device and proliferate or differentiate in an uncontrolled way at off-target sites.²⁰⁹ Although conventional neuromodulatory devices may be switched off or surgically removed if needed, the modulation and removal of tissue-engineered components bring forward several challenges in this regard. Strategies derived from regenerative medicine and immunotherapy may be explored to address these issues, such as engineering cells sensitive to custom external stimuli or with a built-in "kill switch".²¹⁰ Therefore, there is a need to increase our understanding on the long-term adaptations that biohybrid implants and the host nervous system undergo across chronic timeframes to preemptively mitigate any potential risks.

Although biohybrid technologies are still in their infancy, the translation of implantable neurotechnologies is rapidly becoming a reality. This is exemplified by the increasing number of clinical trials approved by the Food and Drug Administration (FDA) that are being carried out by companies such as Synchron and Neuralink. As of 2023, more than 400 clinical trials related to neural interfaces were registered in the Cochrane database. Governments have been involved in the surge for neurotechnology research by launching multiple funding opportunities, such as the BRAIN initiative launched under Obama mandate, or the Stimulating Peripheral Activity to Relieve Conditions (SPARC) common fund. International collaborations have also been established such as the Human Brain Project supported by the European Union. The steady increase in private investment coupled with the rapid growth in artificial intelligence (AI) and machine-learning have greatly accelerated progress in the field of NIs. A growing number of studies have explored the implementation of deep-learning algorithms to enhance the speed and accuracy of speech neuroprostheses driven by implantable BCIs.^{211,212} However, despite this rapid technological advancement, current regulatory, ethical, and legal frameworks are lacking and should be revisited to adapt to these emerging developments. From the regulatory perspective, new categories of medical devices may need to be defined to capture biohybrid technologies with combined traits of active implants, drugs, and cell transplants. Regulatory agencies have already begun to establish specific guidelines for combination products containing two or more regulated components from different categories.¹⁹³ Moreover, the standardisation of criteria from different international agencies is crucial to ensure that clear regulatory pathways are in place.

As biohybrid technologies continue to mature, the development of biointegrative NIs that could remain implanted across the entire lifetime of the user raises several ethical concerns related to privacy, responsibility, agency, and identity.²¹³ Neural data recorded by NIs is highly sensitive since it can be used to decode the thoughts, feelings, or emotions of the user.



It is therefore essential to ensure secure storage and controlled access to this information to prevent misuse by third parties, such as advertisers, employers or governments.²¹⁴ Whether it is perceived as dystopic or utopic, the digitalisation of some aspects of the human mind is becoming a reality, and regulatory and legal frameworks must be pre-emptively defined. The increasing use of AI and closed-loop systems that could operate without input from the user raises multiple issues related to agency and autonomy.²¹⁵ Clinical evidence has shown that ES could influence behaviour and self-determination, which could potentially compromise patient consent.²¹⁶ DBS implantees have reported alterations in perception and embodiment,^{217,218} with some users describing NIs becoming a part of themselves.²¹⁹ Biohybrid NIs also pose several ontological questions that challenge the neuroessentialist view of human identity and consciousness. For instance, neuroethicists have postulated that some form of morally relevant consciousness might develop in complex neural constructs grown *in vitro*, such as brain organoids or assembloids.²²⁰ Moreover, it has been previously postulated that technology could become so utterly intertwined with our cognitive machinery that it could be considered part of the machinery of thought itself.²²¹ Moving forward, these and other metaphysical notions are particularly relevant in the context of biohybrid NIs, as technological progress continues to outpace our fundamental understanding of what it is to be human.

Author contributions

The paper was written by MB with editing by RPL and RG. Funding was obtained by RG.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors acknowledge funding support from the ERC Consolidator Grant in Living Bionics (771985-1). The figures were created with <https://BioRender.com>.

Notes and references

- W. H. Bosking, M. S. Beauchamp and D. Yoshor, *Annu. Rev. Vision Sci.*, 2017, **3**, 141–166.
- M. S. Beauchamp, D. Oswalt, P. Sun, B. L. Foster, J. F. Magnotti, S. Niketeghad, N. Pouratian, W. H. Bosking and D. Yoshor, *Cell*, 2020, **181**, 774–783.e5.
- J. K. Krauss, N. Lipsman, T. Aziz, A. Boutet, P. Brown, J. W. Chang, B. Davidson, W. M. Grill, M. I. Hariz, A. Horn, M. Schulder, A. Mammis, P. A. Tass, J. Volkmann and A. M. Lozano, *Nat. Rev. Neurol.*, 2021, **17**, 75–87.
- P. Rylvlin, S. Rheims, L. J. Hirsch, A. Sokolov and L. Jehi, *Lancet Neurol.*, 2021, **20**, 1038–1047.
- M. Roet, J. Boonstra, E. Sahin, A. E. P. Mulders, A. F. G. Leentjens and A. Jahanshahi, *J. Clin. Med.*, 2020, **9**, 2729.
- B. Kundu, A. A. Brock, D. J. Englot, C. R. Butson and J. D. Rolston, *Neurosurg. Focus*, 2018, **45**, E14.
- D. A. Moses, S. L. Metzger, J. R. Liu, G. K. Anumanchipalli, J. G. Makin, P. F. Sun, J. Chartier, M. E. Dougherty, P. M. Liu, G. M. Abrams, A. Tu-Chan, K. Ganguly and E. F. Chang, *N. Engl. J. Med.*, 2021, **385**, 217–227.
- F. R. Willett, D. T. Avansino, L. R. Hochberg, J. M. Henderson and K. V. Shenoy, *Nature*, 2021, **593**, 249–254.
- S. Waldert, *Front. Neurosci.*, 2016, **10**, 295.
- A. Kilicarslan, S. Prasad, R. G. Grossman and J. L. Contreras-Vidal, in *2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)*, 2013, pp. 5606–5609.
- B. Gunasekera, T. Saxena, R. Bellamkonda and L. Karumbaiiah, *ACS Chem. Neurosci.*, 2015, **6**, 68–83.
- E. M. Maynard, C. T. Nordhausen and R. A. Normann, *Electroencephalogr. Clin. Neurophysiol.*, 1997, **102**, 228–239.
- H. W. Bedell, N. J. Schaub, J. R. Capadona and E. S. Ereifej, *Acta Biomater.*, 2020, **102**, 205–219.
- A. Lecomte, E. Descamps and C. Bergaud, *J. Neural Eng.*, 2018, **15**, 031001.
- K. Woepfel, C. Hughes, A. J. Herrera, J. R. Eles, E. C. Tyler-Kabara, R. A. Gaunt, J. L. Collinger and X. T. Cui, *Front. Bioeng. Biotechnol.*, 2021, **9**, 759711.
- J. C. Williams, J. A. Hippensteel, J. Dilgen, W. Shain and D. R. Kipke, *J. Neural Eng.*, 2007, **4**, 410.
- J. K. Hermann and J. R. Capadona, *Crit. Rev. Bioeng.*, 2018, **46**, 341–367.
- R. D. Dorand, B. L. Benson, L. F. Huang, A. Petrosiute and A. Y. Huang, *Front. Neurosci.*, 2019, **13**, 737.
- C. Bennett, F. Mohammed, A. Álvarez-Ciara, M. A. Nguyen, W. D. Dietrich, S. M. Rajguru, W. J. Streit and A. Prasad, *Biomaterials*, 2019, **188**, 144–159.
- J. W. Salatino, K. A. Ludwig, T. D. Y. Kozai and E. K. Purcell, *Nat. Biomed. Eng.*, 2017, **1**, 862–877.
- F. Lotti, F. Ranieri, G. Vadalà, L. Zollo and G. D. Pino, *Front. Neurosci.*, 2017, **11**, 497.
- Y. Chandorkar, K. Ravikumar and B. Basu, *ACS Biomater. Sci. Eng.*, 2019, **5**, 19–44.
- A. Carnicer-Lombarte, S.-T. Chen, G. G. Malliaras and D. G. Barone, *Front. Bioeng. Biotechnol.*, 2021, **9**, 622524.
- L. Poole-Warren, N. Lovell, S. Baek and R. Green, *Expert Rev. Med. Devices*, 2010, **7**, 35–49.
- D. Prodanov and J. Delbecke, *Front. Neurosci.*, 2016, **10**, 11.
- A. Gilletti and J. Muthuswamy, *J. Neural Eng.*, 2006, **3**, 189.
- C. M. Tringides and D. J. Mooney, *Adv. Mater.*, 2022, **34**, 2107207.
- Y. Wang, X. Yang, X. Zhang, Y. Wang and W. Pei, *Microsyst. Nanoeng.*, 2023, **9**, 7.
- C. H. Thompson, M. J. Zoratti, N. B. Langhals and E. K. Purcell, *Tissue Eng., Part B*, 2016, **22**, 125–135.
- L. J. Szymanski, S. Kellis, C. Y. Liu, K. T. Jones, R. A. Andersen, D. Commins, B. Lee, D. B. McCreery and C. A. Miller, *J. Neural Eng.*, 2021, **18**, 0460b9.
- S. P. Lacour, G. Courtine and J. Guck, *Nat. Rev. Mater.*, 2016, **1**, 1–14.
- S. M. Won, E. Song, J. Zhao, J. Li, J. Rivnay and J. A. Rogers, *Adv. Mater.*, 2018, **30**, 1800534.
- N. Vachicouras, O. Tarabichi, V. V. Kanumuri, C. M. Tringides, J. Macron, F. Fallegger, Y. Thenaisie, L. Epprecht, S. McInturff, A. A. Qureshi, V. Paggi, M. W. Kuklinski, M. C. Brown, D. J. Lee and S. P. Lacour, *Sci. Transl. Med.*, 2019, **11**, eaax9487.
- C. M. Tringides, N. Vachicouras, I. de Lázaro, H. Wang, A. Trouillet, B. R. Seo, A. Elosegui-Artola, F. Fallegger, Y. Shin, C. Casiraghi, K. Kostarelos, S. P. Lacour and D. J. Mooney, *Nat. Nanotechnol.*, 2021, **16**, 1019–1029.
- L. Luan, X. Wei, Z. Zhao, J. J. Siegel, O. Potnis, C. A. Tuppen, S. Lin, S. Kazmi, R. A. Fowler, S. Holloway, A. K. Dunn, R. A. Chitwood and C. Xie, *Sci. Adv.*, 2017, **3**, e1601966.
- Z. J. Du, C. L. Kolarcik, T. D. Y. Kozai, S. D. Luebben, S. A. Sapp, X. S. Zheng, J. A. Nabity and X. T. Cui, *Acta Biomater.*, 2017, **53**, 46–58.
- D. Shi, V. Dhawan and X. T. Cui, *Curr. Opin. Biotechnol.*, 2021, **72**, 54–61.
- A. Sridharan, J. K. Nguyen, J. R. Capadona and J. Muthuswamy, *J. Neural Eng.*, 2015, **12**, 036002.
- Y. Liu, J. Li, S. Song, J. Kang, Y. Tsao, S. Chen, V. Mottini, K. McConnell, W. Xu, Y.-Q. Zheng, J. B.-H. Tok, P. M. George and Z. Bao, *Nat. Biotechnol.*, 2020, **38**, 1031–1036.



- 40 E. Cuttaz, J. Goding, C. Vallejo-Giraldo, U. Aregueta-Robles, N. Lovell, D. Ghezzi and R. A. Green, *Biomater. Sci.*, 2019, **7**, 1372–1385.
- 41 M. Hejazi, W. Tong, M. R. Ibbotson, S. Prawer and D. J. Garrett, *Front. Neurosci.*, 2021, **15**, 658703.
- 42 A. Golabchi, K. M. Woepfel, X. Li, C. F. Lagenaur and X. T. Cui, *Biosens. Bioelectron.*, 2020, **155**, 112096.
- 43 R. Portillo-Lara, J. A. Goding and R. A. Green, *Curr. Opin. Biotechnol.*, 2021, **72**, 62–68.
- 44 T. J. Oxley, N. L. Opie, S. E. John, G. S. Rind, S. M. Ronayne, T. L. Wheeler, J. W. Judy, A. J. McDonald, A. Dornom, T. J. H. Lovell, C. Steward, D. J. Garrett, B. A. Moffat, E. H. Lui, N. Yassi, B. C. V. Campbell, Y. T. Wong, K. E. Fox, E. S. Nurse, I. E. Bennett, S. H. Bauquier, K. A. Liyanage, N. R. van der Nagel, P. Perucca, A. Ahnood, K. P. Gill, B. Yan, L. Churilov, C. R. French, P. M. Desmond, M. K. Horne, L. Kiers, S. Prawer, S. M. Davis, A. N. Burkitt, P. J. Mitchell, D. B. Grayden, C. N. May and T. J. O'Brien, *Nat. Biotechnol.*, 2016, **34**, 320–327.
- 45 T. J. Oxley, P. E. Yoo, G. S. Rind, S. M. Ronayne, C. M. S. Lee, C. Bird, V. Hampshire, R. P. Sharma, A. Morokoff, D. L. Williams, C. MacIsaac, M. E. Howard, L. Irving, I. Vrljic, C. Williams, S. E. John, F. Weissenborn, M. Dzenko, A. H. Balabanski, D. Friedenber, A. N. Burkitt, Y. T. Wong, K. J. Drummond, P. Desmond, D. Weber, T. Denison, L. R. Hochberg, S. Mathers, T. J. O'Brien, C. N. May, J. Mocco, D. B. Grayden, B. C. V. Campbell, P. Mitchell and N. L. Opie, *J. Neurointerv. Surg.*, 2021, **13**, 102–108.
- 46 R. A. Green, *APL Bioeng.*, 2021, **5**, 040401.
- 47 G. E. Slaughter, E. Bieberich, G. E. Wnek, K. J. Wynne and A. Guiseppe-Elie, *Langmuir*, 2004, **20**, 7189–7200.
- 48 E. Azemi, C. F. Lagenaur and X. T. Cui, *Biomaterials*, 2011, **32**, 681–692.
- 49 T. Numakawa, S. Suzuki, E. Kumamaru, N. Adachi, M. Richards and H. Kunugi, *Histol. Histopathol.*, 2010, **25**, 237–258.
- 50 Y. Jiao, B. Palmgren, E. Novozhilova, U. Englund Johansson, A. L. Spieles-Engemann, A. Kale, S. I. Stupp and P. Olivius, *BioMed Res. Int.*, 2014, **2014**, 356415.
- 51 M. L. Block, L. Zecca and J.-S. Hong, *Nat. Rev. Neurosci.*, 2007, **8**, 57–69.
- 52 J. R. Eles, A. L. Vazquez, N. R. Snyder, C. Lagenaur, M. C. Murphy, T. D. Y. Kozai and X. T. Cui, *Biomaterials*, 2017, **113**, 279–292.
- 53 J. Slavik, J. Skopalik, I. Provaznik and J. Hubálek, *Sensors*, 2019, **19**, 5379.
- 54 C. Chen, X. Kong and I.-S. Lee, *Biomed. Mater.*, 2015, **11**, 014108.
- 55 E. Azemi, G. T. Gobbel and X. T. Cui, *J. Neurosurg.*, 2010, **113**, 673–681.
- 56 S. Khan and G. Newaz, *J. Biomed. Mater. Res., Part A*, 2010, **93A**, 1209–1224.
- 57 G. L. Mario Cheong, K. S. Lim, A. Jakubowicz, P. J. Martens, L. A. Poole-Warren and R. A. Green, *Acta Biomater.*, 2014, **10**, 1216–1226.
- 58 R. Wadhwa, C. F. Lagenaur and X. T. Cui, *J. Controlled Release*, 2006, **110**, 531–541.
- 59 C. Boehler, C. Kleber, N. Martini, Y. Xie, I. Dryg, T. Stieglitz, U. G. Hofmann and M. Asplund, *Biomaterials*, 2017, **129**, 176–187.
- 60 N. Bhagwat, R. E. Murray, S. I. Shah, K. L. Kiick and D. C. Martin, *Acta Biomater.*, 2016, **41**, 235–246.
- 61 J. A. Chikar, J. L. Hendricks, S. M. Richardson-Burns, Y. Raphael, B. E. Pfingst and D. C. Martin, *Biomaterials*, 2012, **33**, 1982–1990.
- 62 S. Kim, Y. Jang, M. Jang, A. Lim, J. G. Hardy, H. S. Park and J. Y. Lee, *Acta Biomater.*, 2018, **80**, 258–268.
- 63 S. Kim, L. K. Jang, M. Jang, S. Lee, J. G. Hardy and J. Y. Lee, *ACS Appl. Mater. Interfaces*, 2018, **10**, 33032–33042.
- 64 R. A. Green, N. H. Lovell and L. A. Poole-Warren, *Acta Biomater.*, 2010, **6**, 63–71.
- 65 R. A. Green, N. H. Lovell and L. A. Poole-Warren, *Biomaterials*, 2009, **30**, 3637–3644.
- 66 J. Goding, A. Gilmour, P. Martens, L. Poole-Warren and R. Green, *Adv. Healthcare Mater.*, 2017, **6**, 1601177.
- 67 C. A. R. Chapman, E. A. Cuttaz, J. A. Goding and R. A. Green, *Appl. Phys. Lett.*, 2020, **116**, 010501.
- 68 Y. N. Kang, N. Chou, J.-W. Jang, H. K. Choe and S. Kim, *Microsyst. Nanoeng.*, 2021, **7**, 1–11.
- 69 W. Shen, S. Das, F. Vitale, A. Richardson, A. Ananthakrishnan, L. A. Struzyna, D. P. Brown, N. Song, M. Ramkumar, T. Lucas, D. K. Cullen, B. Litt and M. G. Allen, *Microsyst. Nanoeng.*, 2018, **4**, 1–15.
- 70 A. Fanelli and D. Ghezzi, *Curr. Opin. Biotechnol.*, 2021, **72**, 22–28.
- 71 L. Ferlauto, P. Vagni, A. Fanelli, E. G. Zollinger, K. Monsorno, R. C. Paolicelli and D. Ghezzi, *Biomaterials*, 2021, **274**, 120889.
- 72 W. Cho, S. Yoon and T. D. Chung, *Chem. Sci.*, 2023, **14**, 4463–4479.
- 73 V. Brunetti, G. Maiorano, L. Rizzello, B. Sorce, S. Sabella, R. Cingolani and P. P. Pompa, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 6264–6269.
- 74 S. P. Khan, G. G. Auner and G. M. Newaz, *Nanomedicine*, 2005, **1**, 125–129.
- 75 C. A. R. Chapman, H. Chen, M. Stamou, J. Biener, M. M. Biener, P. J. Lein and E. Seker, *ACS Appl. Mater. Interfaces*, 2015, **7**, 7093–7100.
- 76 R. Lahoud, *MPhil thesis*, American University of Beirut, 2021.
- 77 M. J. Vassey, G. P. Figueredo, D. J. Scurr, A. S. Vasilevich, S. Vermeulen, A. Carlier, J. Luckett, N. R. M. Beijer, P. Williams, D. A. Winkler, J. de Boer, A. M. Ghaemmaghami and M. R. Alexander, *Adv. Sci.*, 2020, **7**, 1903392.
- 78 N. E. Paul, C. Skazik, M. Harwardt, M. Bartneck, B. Denecke, D. Klee, J. Salber and G. Zwadlo-Klarwasser, *Biomaterials*, 2008, **29**, 4056–4064.
- 79 R. Ahmed and K. Reifsnider, *Int. J. Electrochem. Sci.*, 2011, 1159–1174.
- 80 J. P. Seymour and D. R. Kipke, in 2006 International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, pp. 4606–4609.
- 81 P. R. Kennedy, *J. Neurosci. Methods*, 1989, **29**, 181–193.
- 82 P. R. Kennedy, S. S. Mirra and R. A. E. Bakay, *Neurosci. Lett.*, 1992, **142**, 89–94.
- 83 J. T. W. Kuo, B. J. Kim, S. A. Hara, C. D. Lee, C. A. Gutierrez, T. Q. Hoang and E. Meng, *Lab Chip*, 2013, **13**, 554–561.
- 84 S. A. Hara, B. J. Kim, J. T. W. Kuo, C. D. Lee, E. Meng and V. Pikov, *J. Neural Eng.*, 2016, **13**, 066020.
- 85 P. R. Patel, K. Na, H. Zhang, T. D. Y. Kozai, N. A. Kotov, E. Yoon and C. A. Chestek, *J. Neural Eng.*, 2015, **12**, 046009.
- 86 F. He, R. Lycke, M. Ganji, C. Xie and L. Luan, *iScience*, 2020, **23**, 101387.
- 87 J. L. Skousen, S. M. E. Merriam, O. Srivannavit, G. Perlin, K. D. Wise and P. A. Tresco, in *Progress in Brain Research*, ed. J. Schouenborg, M. Garwicz and N. Danielsen, Elsevier, 2011, vol. 194, pp. 167–180.
- 88 Implantable “Neural Dust” Enables Precise Wireless Recording of Nerve Activity, <https://www.darpa.mil/news-events/2016-08-03>, (accessed January 24, 2023).
- 89 K. Patch, *Nat. Biotechnol.*, 2021, **39**, 255–256.
- 90 X. Yang, T. Zhou, T. J. Zwang, G. Hong, Y. Zhao, R. D. Viveros, T.-M. Fu, T. Gao and C. M. Lieber, *Nat. Mater.*, 2019, **18**, 510–517.
- 91 T. Chung, J. Q. Wang, J. Wang, B. Cao, Y. Li and S. W. Pang, *J. Neural Eng.*, 2015, **12**, 056018.
- 92 M. A. Elms, mscresearch, University of Leeds, 2017.
- 93 R. T. Hassarati, W. F. Dueck, C. Tasche, P. M. Carter, L. A. Poole-Warren and R. A. Green, *Trans. Neural Syst. Rehabil. Eng.*, 2014, **22**, 411–418.
- 94 R. A. Green, R. T. Hassarati, J. A. Goding, S. Baek, N. H. Lovell, P. J. Martens and L. A. Poole-Warren, *Macromol. Biosci.*, 2012, **12**, 494–501.
- 95 G. Hong, X. Yang, T. Zhou and C. M. Lieber, *Curr. Opin. Neurobiol.*, 2018, **50**, 33–41.
- 96 J. Liu, T.-M. Fu, Z. Cheng, G. Hong, T. Zhou, L. Jin, M. Duvvuri, Z. Jiang, P. Kruskal, C. Xie, Z. Suo, Y. Fang and C. M. Lieber, *Nat. Nanotechnol.*, 2015, **10**, 629–636.
- 97 C. Xie, J. Liu, T.-M. Fu, X. Dai, W. Zhou and C. M. Lieber, *Nat. Mater.*, 2015, **14**, 1286–1292.
- 98 T.-M. Fu, G. Hong, T. Zhou, T. G. Schuhmann, R. D. Viveros and C. M. Lieber, *Nat. Methods*, 2016, **13**, 875–882.
- 99 T. Zhou, G. Hong, T.-M. Fu, X. Yang, T. G. Schuhmann, R. D. Viveros and C. M. Lieber, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, 5894–5899.
- 100 S. M. Richardson-Burns, J. L. Hendricks and D. C. Martin, *J. Neural Eng.*, 2007, **4**, L6.
- 101 S. M. Richardson-Burns, J. L. Hendricks, B. Foster, L. K. Povlich, D.-H. Kim and D. C. Martin, *Biomaterials*, 2007, **28**, 1539–1552.



- 102 S. J. Wilks, A. J. Woolley, L. Ouyang, D. C. Martin and K. J. Otto, in 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2011, pp. 5412–5415.
- 103 L. Ouyang, C. L. Shaw, C. Kuo, A. L. Griffin and D. C. Martin, *J. Neural Eng.*, 2014, **11**, 026005.
- 104 R. T. Rihani, A. M. Stiller, J. O. Usoro, J. Lawson, H. Kim, B. J. Black, V. R. Danda, J. Maeng, V. D. Varner, T. H. Ware and J. J. Pancrazio, *Acta Biomater.*, 2020, **111**, 54–64.
- 105 D. O. Adewole, M. D. Serruya, J. A. Wolf and D. K. Cullen, *Front. Neurosci.*, 2019, **13**, 269.
- 106 A. E. Pereda, *Nat. Rev. Neurosci.*, 2014, **15**, 250–263.
- 107 D. W. Munno and N. I. Syed, *J. Physiol.*, 2003, **552**, 1–11.
- 108 M. J. Vaughn and J. S. Haas, *Front. Cell. Neurosci.*, 2022, **16**, 910015.
- 109 R. A. Green, K. S. Lim, W. C. Henderson, R. T. Hassarati, P. J. Martens, N. H. Lovell and L. A. Poole-Warren, in 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), 2013, pp. 6957–6960.
- 110 R. K. Shepherd, *Neurobionics: The Biomedical Engineering of Neural Prostheses*, John Wiley & Sons, 2016.
- 111 A. E. Rochford, A. Carnicer-Lombarte, V. F. Curto, G. G. Malliaras and D. G. Barone, *Adv. Mater.*, 2020, **32**, 1903182.
- 112 I. S. Alferiev, B. Hooshdar, B. B. Pressly, P. W. Zoltick, S. J. Stachelek, M. Chorny, R. J. Levy and I. Fishbein, *Sci. Rep.*, 2022, **12**, 19212.
- 113 S. Feng, Z. Yan, C. Guo, Z. Chen, K. Zhang, X. Mo and Y. Gu, *J. Biomed. Mater. Res., Part A*, 2011, **97**, 321–329.
- 114 N. A. Peppas, B. V. Slaughter and M. A. Kanzelberger, in *Polymer Science: A Comprehensive Reference*, ed. K. Matyjaszewski and M. Möller, Elsevier, Amsterdam, 2012, pp. 385–395.
- 115 S. De Faveri, E. Maggolini, E. Miele, F. De Angelis, F. Cesca, F. Benfenati and L. Fadiga, *Front. Neuroeng.*, 2014, **7**(7).
- 116 J. A. Goding, A. D. Gilmour, U. A. Aregueta-Robles, E. A. Hasan and R. A. Green, *Adv. Funct. Mater.*, 2018, **28**, 1702969.
- 117 K. R. Jessen, *Int. J. Biochem. Cell Biol.*, 2004, **36**, 1861–1867.
- 118 C. S. von Bartheld, J. Bahney and S. Herculano-Houzel, *J. Comp. Neurol.*, 2016, **524**, 3865–3895.
- 119 *Glial Cells in Health and Disease of the CNS*, ed. R. von Bernhardi, Springer International Publishing, Cham, 2016, vol. 949.
- 120 Y. Bamba, T. Shofuda, D. Kanematsu, M. Nonaka, M. Yamasaki, H. Okano and Y. Kanemura, *Biochem. Biophys. Res. Commun.*, 2014, **447**, 683–688.
- 121 M. P. Lichtenstein, N. M. Carretero, E. Pérez, M. Pulido-Salgado, J. Moral-Vico, C. Solà, N. Casañ-Pastor and C. Suñol, *Neurotoxicology*, 2018, **68**, 115–125.
- 122 U. A. Aregueta-Robles, P. J. Martens, L. A. Poole-Warren and R. A. Green, *J. Polym. Sci., Part B: Polym. Phys.*, 2018, **56**, 273–287.
- 123 U. A. Aregueta-Robles, K. S. Lim, P. J. Martens, N. H. Lovell, L. A. Poole-Warren and R. Green, in 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), 2015, pp. 2600–2603.
- 124 C. Vallejo-Giraldo, M. Genta, O. Cauvi, J. Goding and R. Green, *Front. Bioeng. Biotechnol.*, 2020, **8**, 601704.
- 125 K. Takahashi and S. Yamanaka, *Cell*, 2006, **126**, 663–676.
- 126 H. Okano, *Trends Mol. Med.*, 2022, **28**, 897–899.
- 127 K.-C. Sonntag, B. Song, N. Lee, J. H. Jung, Y. Cha, P. Leblanc, C. Neff, S. W. Kong, B. S. Carter, J. Schweitzer and K.-S. Kim, *Prog. Neurobiol.*, 2018, **168**, 1–20.
- 128 N. Nagoshi and H. Okano, *Cell. Mol. Life Sci.*, 2018, **75**, 989–1000.
- 129 F. Sivandzade and L. Cucullo, *Int. J. Mol. Sci.*, 2021, **22**, 2153.
- 130 M. Lam, T. Sanosaka, A. Lundin, K. Imaizumi, D. Etal, F. H. Karlsson, M. Clausen, J. Cairns, R. Hicks, J. Kohyama, M. Kele, H. Okano and A. Falk, *Genes Cells*, 2019, **24**, 836–847.
- 131 B. S. Casas, G. Vitória, M. N. do Costa, R. Madeiro da Costa, P. Trindade, R. Maciel, N. Navarrete, S. K. Rehen and V. Palma, *Transl. Psychiatry*, 2018, **8**, 1–15.
- 132 J. Triebelhorn, I. Cardon, K. Kuffner, S. Bader, T. Jahner, K. Meindl, T. Rothhammer-Hampl, M. J. Riemenschneider, K. Drexler, M. Bernburg, C. Nothdurfter, A. Manook, C. Brochhausen, T. C. Baghai, S. Hilbert, R. Rupprecht, V. M. Milenkovic and C. H. Wetzel, *Mol. Psychiatry*, 2022, 1–11.
- 133 M. Ohnuki and K. Takahashi, *Philos. Trans. R. Soc., B*, 2015, **370**, 20140367.
- 134 D. Hockemeyer and R. Jaenisch, *Cell Stem Cell*, 2016, **18**, 573–586.
- 135 S. Peressotti, G. E. Koehl, J. A. Goding and R. A. Green, *ACS Biomater. Sci. Eng.*, 2021, **7**, 4136–4163.
- 136 A. D. Theocharis, S. S. Skandalis, C. Gialeli and N. K. Karamanos, *Adv. Drug Delivery Rev.*, 2016, **97**, 4–27.
- 137 J. L. Drury and D. J. Mooney, *Biomaterials*, 2003, **24**, 4337–4351.
- 138 S. J. Bidarra, C. C. Barrias and P. L. Granja, *Acta Biomater.*, 2014, **10**, 1646–1662.
- 139 S. A. DeLong, A. S. Gobin and J. L. West, *J. Controlled Release*, 2005, **109**, 139–148.
- 140 K. Y. Lee and D. J. Mooney, *Prog. Polym. Sci.*, 2012, **37**, 106–126.
- 141 I. Sandvig, K. Karstensen, A. M. Rokstad, F. L. Aachmann, K. Formo, A. Sandvig, G. Skjåk-Bræk and B. L. Strand, *J. Biomed. Mater. Res., Part A*, 2015, **103**, 896–906.
- 142 R. Boni, A. Ali, A. Shavandi and A. N. Clarkson, *J. Biomed. Sci.*, 2018, **25**, 90.
- 143 M. C. Catoira, L. Fusaro, D. Di Francesco, M. Ramella and F. Boccafroschi, *J. Mater. Sci.: Mater. Med.*, 2019, **30**, 115.
- 144 S. Chattopadhyay and R. T. Raines, *Biopolymers*, 2014, **101**, 821–833.
- 145 M. Genta, PhD thesis, Imperial College London, 2023.
- 146 D. Hoffman-Kim, J. A. Mitchel and R. V. Bellamkonda, *Annu. Rev. Biomed. Eng.*, 2010, **12**, 203–231.
- 147 R. D. Bierman-Duquette, G. Safarians, J. Huang, B. Rajput, J. Y. Chen, Z. Z. Wang and S. K. Seidlits, *Adv. Healthcare Mater.*, 2022, **11**, 2101577.
- 148 F. Yang, R. Murugan, S. Wang and S. Ramakrishna, *Biomaterials*, 2005, **26**, 2603–2610.
- 149 M. D. Tang-Schomer, X. Hu, M. Hronik-Tupaj, L. W. Tien, M. J. Whalen, F. G. Omenetto and D. L. Kaplan, *Adv. Funct. Mater.*, 2014, **24**, 1938–1948.
- 150 A. W. Orr, B. P. Helmke, B. R. Blackman and M. A. Schwartz, *Dev. Cell*, 2006, **10**, 11–20.
- 151 J. M. Barnes, L. Przybyla and V. M. Weaver, *J. Cell Sci.*, 2017, **130**, 71–82.
- 152 A. Banerjee, M. Arha, S. Choudhary, R. S. Ashton, S. R. Bhatia, D. V. Schaffer and R. S. Kane, *Biomaterials*, 2009, **30**, 4695–4699.
- 153 A. I. Teixeira, S. Ilkhanizadeh, J. A. Wigenius, J. K. Duckworth, O. Inganäs and O. Hermanson, *Biomaterials*, 2009, **30**, 4567–4572.
- 154 O. Chaudhuri, L. Gu, M. Darnell, D. Klumpers, S. A. Bencherif, J. C. Weaver, N. Huebsch and D. J. Mooney, *Nat. Commun.*, 2015, **6**, 6365.
- 155 O. Chaudhuri, L. Gu, D. Klumpers, M. Darnell, S. A. Bencherif, J. C. Weaver, N. Huebsch, H. Lee, E. Lippens, G. N. Duda and D. J. Mooney, *Nat. Mater.*, 2016, **15**, 326–334.
- 156 O. Chaudhuri, J. Cooper-White, P. A. Janmey, D. J. Mooney and V. B. Shenoy, *Nature*, 2020, **584**, 535–546.
- 157 C. Cassel de Camps, S. Aslani, N. Stylianesis, H. Nami, N.-V. Mohamed, T. M. Durcan and C. Moraes, *ACS Appl. Bio Mater.*, 2022, **5**, 214–224.
- 158 S. P. Lacour, S. Benmerah, E. Tarte, J. FitzGerald, J. Serra, S. McMahon, J. Fawcett, O. Graudejus, Z. Yu and B. Morrison, *Med. Biol. Eng. Comput.*, 2010, **48**, 945–954.
- 159 E. R. Aurand, K. J. Lampe and K. B. Bjurstad, *Neurosci. Res. Lett.*, 2012, **72**, 199–213.
- 160 K. Saha, A. J. Keung, E. F. Irwin, Y. Li, L. Little, D. V. Schaffer and K. E. Healy, *Biophys. J.*, 2008, **95**, 4426–4438.
- 161 A. Carnicer-Lombarte, D. G. Barone, I. B. Dimov, R. S. Hamilton, M. Prater, X. Zhao, A. L. Rutz, G. G. Malliaras, S. P. Lacour, C. E. Bryant, J. W. Fawcett and K. Franze, *bioRxiv*, 2022, preprint, DOI: [10.1101/829648](https://doi.org/10.1101/829648).
- 162 C. Bertucci, R. Koppes, C. Dumont and A. Koppes, *Brain Res. Bull.*, 2019, **152**, 265–284.
- 163 N. Yamamoto and G. López-Bendito, *Eur. J. Neurosci.*, 2012, **35**, 1595–1604.
- 164 X.-L. Yin, H.-Q. Jie, M. Liang, L.-N. Gong, H.-W. Liu, H.-L. Pan, Y.-Z. Xing, H.-B. Shi, C.-Y. Li, L.-Y. Wang and S.-K. Yin, *Front. Mol. Neurosci.*, 2018, **11**, 183.
- 165 F. J. Martini, T. Guillamón-Vivancos, V. Moreno-Juan, M. Valdeolmillos and G. López-Bendito, *Neuron*, 2021, **109**, 2519–2534.
- 166 H. J. Luhmann, A. Sinning, J.-W. Yang, V. Reyes-Puerta, M. C. Stüttgen, S. Kirischuk and W. Kilb, *Front. Neural Circuits*, 2016, **10**, 40.



- 167 A. Burnstine-Townley, Y. Eshel and N. Amdursky, *Adv. Funct. Mater.*, 2020, **30**, 1901369.
- 168 J. H. Min, M. Patel and W.-G. Koh, *Polymers*, 2018, **10**, 1078.
- 169 M. Imaninezhad, K. Pemberton, F. Xu, K. Kalinowski, R. Bera and S. P. Zustiak, *J. Neural Eng.*, 2018, **15**, 056034.
- 170 K. Baranes, M. Shevach, O. Shefi and T. Dvir, *Nano Lett.*, 2016, **16**, 2916–2920.
- 171 N. Saderi, M. Rajabi, B. Akbari, M. Firouzi and Z. Hassannejad, *J. Mater. Sci.: Mater. Med.*, 2018, **29**, 134.
- 172 A. Vashist, A. Kaushik, A. Vashist, V. Sagar, A. Ghosal, Y. K. Gupta, S. Ahmad and M. Nair, *Adv. Healthcare Mater.*, 2018, **7**, 1701213.
- 173 V. Lovat, D. Pantarotto, L. Lagostena, B. Cacciari, M. Grandolfo, M. Righi, G. Spalluto, M. Prato and L. Ballerini, *Nano Lett.*, 2005, **5**, 1107–1110.
- 174 A. Fabbro, A. Villari, J. Laishram, D. Scaini, F. M. Toma, A. Turco, M. Prato and L. Ballerini, *ACS Nano*, 2012, **6**, 2041–2055.
- 175 A. N. Koppes, K. W. Keating, A. L. McGregor, R. A. Koppes, K. R. Kearns, A. M. Ziemba, C. A. McKay, J. M. Zuidema, C. J. Rivet, R. J. Gilbert and D. M. Thompson, *Acta Biomater.*, 2016, **39**, 34–43.
- 176 O. Akhavan, E. Ghaderi, S. A. Shirazian and R. Rahighi, *Carbon*, 2016, **97**, 71–77.
- 177 L. Sordini, F. F. F. Garrudo, C. A. V. Rodrigues, R. J. Linhardt, J. M. S. Cabral, F. C. Ferreira and J. Morgado, *Front. Bioeng. Biotechnol.*, 2021, **9**, 591838.
- 178 R. Green and M. R. Abidian, *Adv. Mater.*, 2015, **27**, 7620–7637.
- 179 D.-H. Kim, S. Richardson-Burns, L. Povlich, M. R. Abidian, S. Spanninga, J. L. Hendricks and D. C. Martin, in *Indwelling Neural Implants: Strategies for Contending with the In Vivo Environment*, ed. W. M. Reichert, CRC Press/Taylor & Francis, Boca Raton (FL), 2008.
- 180 S. V. Velankar, V. Lai and R. A. Vaia, *ACS Appl. Mater. Interfaces*, 2012, **4**, 24–29.
- 181 A. Augustine, M. Veillerot, N. Gauthier, B. Zhu, C.-Y. Hui, Y. Tran, E. Verneuil and A. Chateauminois, *Soft Matter*, 2023, **19**, 5169–5178.
- 182 A. N. Dalrymple, U. A. Robles, M. Huynh, B. A. Nayagam, R. A. Green, L. A. Poole-Warren, J. B. Fallon and R. K. Shepherd, *J. Neural Eng.*, 2020, **17**, 026018.
- 183 T. Hyakumura, U. Aregueta-Robles, W. Duan, J. Villalobos, W. K. Adams, L. Poole-Warren and J. B. Fallon, *Front. Neurosci.*, 2021, **15**, 761525.
- 184 K. C. Spencer, J. C. Sy, K. B. Ramadi, A. M. Graybiel, R. Langer and M. J. Cima, *Sci. Rep.*, 2017, **7**, 1952.
- 185 C. M. Tringides, M. Boulingre, A. Khalil, T. Lungjangwa, R. Jaenisch and D. J. Mooney, *Adv. Healthcare Mater.*, 2023, **12**, 2202221.
- 186 D. O. Adewole, L. A. Struzyna, J. C. Burrell, J. P. Harris, A. D. Nemes, D. Petrov, R. H. Kraft, H. I. Chen, M. D. Serruya, J. A. Wolf and D. K. Cullen, *Sci. Adv.*, 2021, **7**, eaay5347.
- 187 L. A. Struzyna, J. P. Harris, K. S. Katiyar, H. I. Chen and D. K. Cullen, *Neural Regen. Res.*, 2015, **10**, 679–685.
- 188 L. A. Struzyna, J. A. Wolf, C. J. Mietus, D. O. Adewole, H. I. Chen, D. H. Smith and D. K. Cullen, *Tissue Eng., Part A*, 2015, **21**(21–22).
- 189 V. S. Polikov, M. L. Block, J.-M. Fellous, J.-S. Hong and W. M. Reichert, *Biomaterials*, 2006, **27**, 5368–5376.
- 190 T. M. Dawson, T. E. Golde and C. L. Tourenne, *Nat. Neurosci.*, 2018, **21**, 1370–1379.
- 191 T. D. Y. Kozai, A. L. Vazquez, C. L. Weaver, S.-G. Kim and X. T. Cui, *J. Neural Eng.*, 2012, **9**, 066001.
- 192 R. Tognatta, M. Merlini, Z. Yan, R. Schuck, D. Davalos and K. Akassoglou, *STAR Protoc.*, 2021, **2**, 100638.
- 193 A. Fernández-Colino, F. Kiessling, I. Slabu, L. De Laporte, P. Akhyari, S. K. Nagel, J. Stingl, S. Reese and S. Jockenhoevel, *Adv. Healthcare Mater.*, 2023, **12**, 2300991.
- 194 S. S. Dalal, E. Edwards, H. E. Kirsch, N. M. Barbaro, R. T. Knight and S. S. Nagarajan, *J. Neurosci. Methods*, 2008, **174**, 106–115.
- 195 C. Rabut, S. Yoo, R. C. Hurt, Z. Jin, H. Li, H. Guo, B. Ling and M. G. Shapiro, *Neuron*, 2020, **108**, 93–110.
- 196 T. Deffieux, C. Demeñe and M. Tanter, *Neuroscience*, 2021, **474**, 110–121.
- 197 S. H. Kim, J. S. Kwon, J. G. Cho, K. G. Park, T. H. Lim, M. S. Kim, H. S. Choi, C. H. Park and S. J. Lee, *Bioeng. Transl. Med.*, 2021, **6**, e10216.
- 198 R. Guzman, N. Uchida, T. M. Bliss, D. He, K. K. Christopherson, D. Stellwagen, A. Capela, J. Greve, R. C. Malenka, M. E. Moseley, T. D. Palmer and G. K. Steinberg, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 10211–10216.
- 199 S. R. Kane, S. F. Cogan, J. Ehrlich, T. D. Plante, D. B. McCreery and P. R. Troyk, *IEEE Trans. Biomed. Eng.*, 2013, **60**, 2153–2160.
- 200 N. A. Alba, Z. J. Du, K. A. Catt, T. D. Y. Kozai and X. T. Cui, *Biosensors*, 2015, **5**, 618–646.
- 201 C.-F. V. Latchoumane, L. Jackson, M. S. E. Sendi, K. F. Tehrani, L. J. Mortensen, S. L. Stice, M. Ghovanloo and L. Karumbaiyah, *Sci. Rep.*, 2018, **8**, 10957.
- 202 M. O'Hara-Wright, S. Mobini and A. Gonzalez-Cordero, *Front. Cell Dev. Biol.*, 2022, **10**, 901652.
- 203 J. Zimmermann, F. Sahm, N. Arbeiter, H. Bathel, Z. Song, R. Bader, A. Jonitz-Heincke and U. van Rienen, *Bioelectrochemistry*, 2023, **151**, 108395.
- 204 N. Even-Chen, D. G. Muratore, S. D. Stavisky, L. R. Hochberg, J. M. Henderson, B. Murmann and K. V. Shenoy, *Nat. Biomed. Eng.*, 2020, **4**, 984–996.
- 205 S. M. Won, L. Cai, P. Gutruf and J. A. Rogers, *Nat. Biomed. Eng.*, 2023, **7**, 405–423.
- 206 J. D. Simeral, T. Hosman, J. Saab, S. N. Flesher, M. Vilela, B. Franco, J. N. Kelemen, D. M. Brandman, J. G. Cianciello, P. G. Rezaii, E. N. Eskandar, D. M. Rosler, K. V. Shenoy, J. M. Henderson, A. V. Nurmikko and L. R. Hochberg, *IEEE Trans. Biomed. Eng.*, 2021, **68**, 2313–2325.
- 207 A. B. Rapeaux and T. G. Constandinou, *Curr. Opin. Biotechnol.*, 2021, **72**, 102–111.
- 208 P. Limousin and T. Foltynie, *Nat. Rev. Neurol.*, 2019, **15**, 234–242.
- 209 A. S. Lee, C. Tang, M. S. Rao, I. L. Weissman and J. C. Wu, *Nat. Med.*, 2013, **19**, 998–1004.
- 210 Strategies to Control CAR-T Cell Therapy, <https://insights.bio/cell-and-gene-therapy-insights/journal/article/336/Strategies-to-Control-CAR-T-Cell-Therapy-Perspective-on-Next-Generation-CARs>, (accessed August 24, 2023).
- 211 S. L. Metzger, K. T. Littlejohn, A. B. Silva, D. A. Moses, M. P. Seaton, R. Wang, M. E. Dougherty, J. R. Liu, P. Wu, M. A. Berger, I. Zhuravleva, A. Tu-Chan, K. Ganguly, G. K. Anumanchipalli and E. F. Chang, *Nature*, 2023, **620**, 1037–1046.
- 212 F. R. Willett, E. M. Kunz, C. Fan, D. T. Avansino, G. H. Wilson, E. Y. Choi, F. Kamdar, M. F. Glasser, L. R. Hochberg, S. Druckmann, K. V. Shenoy and J. M. Henderson, *Nature*, 2023, **620**, 1031–1036.
- 213 T. Stieglitz, *Neuroethics*, 2021, **14**, 5–16.
- 214 R. Portillo-Lara, B. Tahirbegi, C. A. R. Chapman, J. A. Goding and R. A. Green, *APL Bioeng.*, 2021, **5**, 031507.
- 215 K. Jebari, *Neuroethics*, 2013, **6**, 617–625.
- 216 J. Clausen, *Neuroethics*, 2013, **6**, 429–434.
- 217 L. Drew, *Nature*, 2019, **571**, S19–S21.
- 218 F. Gilbert, A. Brown, I. Dasgupta, H. Martens, E. Klein and S. Goering, *Neuroethics*, 2021, **14**, 333–340.
- 219 F. Gilbert, M. Ienca and M. Cook, *Brain-Stimul.*, 2023, **16**, 783–789.
- 220 T. Sawai, Y. Hayashi, T. Niikawa, J. Shepherd, E. Thomas, T.-L. Lee, A. Erler, M. Watanabe and H. Sakaguchi, *AJOB Neurosci.*, 2022, **13**, 81–94.
- 221 A. Clark and D. Chalmers, *Analysis*, 1998, **58**, 7–19.

